Amylyx Pharmaceuticals, Inc. (AMLX) Dividend History

Amylyx Pharmaceuticals, Inc. is a biotechnology company focused on developing treatments for neurodegenerative diseases. The company is known for its innovative approach combining neuroscience and clinical research to address conditions such as amyotrophic lateral sclerosis (ALS) and other neurodegenerative disorders. Amylyx's leading product candidate, AMX0035, is designed to potentially slow disease progression and improve patient quality of life.

43 Thorndike Street, Cambridge, MA, 02141
Phone: 617-683-0917
Website:

Dividend History

Pay Date Amount Ex Dividend Date Record Date
April 02, 2018 $0.42 03/28/2018 03/29/2018
January 02, 2018 $0.36 12/28/2017 12/29/2017
October 02, 2017 $0.24 09/28/2017 09/29/2017

Dividends Summary

  • Amylyx Pharmaceuticals, Inc. has issued 3 dividends over a period of about a year
  • The most recent dividend was paid 2623 days ago, on April 2, 2018
  • The first recorded dividend was paid on October 2, 2017
  • The highest dividend payout was $0.42 per share
  • The average dividend over this 1 year span is $0.34 per share
  • Amylyx Pharmaceuticals, Inc. has increased its dividend payments by 74.27% since 2017

Company News

  • Why Amylyx Pharmaceuticals Stock Was So Healthy This Week

    Amylyx Pharmaceuticals' stock rose over 10% this week after the company reported positive results from a phase 2 clinical trial of its drug AMX0035 for the rare genetic disorder Wolfram Syndrome. The treatment was well-tolerated and showed sustained improvement in pancreatic function, leading the company to plan discussions with the FDA about advancing the drug to phase 3 testing.

    The Motley Fool
  • Breaking Down Amylyx Pharma: 9 Analysts Share Their Views

    Amylyx Pharma (NASDAQ:AMLX) underwent analysis by 9 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 6 0 3 0 0 Last 30D 1 0 0 0 0 1M Ago 1 0 1 0 0 2M Ago 3 0 2 0 0 3M Ago 1 0 0 0 0 Insights from analysts' 12-month price targets are revealed, presenting an average target of $9.22, a high estimate of $32.00, and a low estimate of $3.00. Highlighting a 66.73% decrease, the current average has fallen from the previous average price target of $27.71. Interpreting Analyst Ratings: A Closer Look A comprehensive examination of how financial experts perceive Amylyx Pharma is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Andrew Fein HC Wainwright & Co. Maintains Buy $8.00 - Joel Beatty Baird Lowers Neutral $3.00 $4.00 Andrew Fein HC Wainwright & Co. Maintains Buy $8.00 - Andrew Fein HC Wainwright & Co. Maintains Buy $8.00 $8.00 Andrew Fein HC Wainwright & Co. Lowers Buy $8.00 $42.00 Neena Bitritto-Garg Deutsche Bank Lowers Buy $8.00 $36.00 Chris Shibutani Goldman Sachs Lowers Neutral $4.00 $40.00 Joel Beatty Baird Lowers Neutral $4.00 $37.00 Graig Suvannavejh Mizuho Raises Buy $32.00 $27.00 Key Insights: Action Taken: Responding to changing market ...Full story available on Benzinga.com

    Benzinga
  • Amylyx Pharmaceuticals, Inc. (AMLX) Reports Q1 Loss, Lags Revenue Estimates

    Amylyx Pharmaceuticals (AMLX) delivered earnings and revenue surprises of -291.67% and 21.74%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

    Zacks Investment Research
  • The Zacks Analyst Blog Highlights Bristol Myers, Moderna, 2seventy bio, Amylyx Pharmaceuticals and Syros Pharmaceuticals

    Bristol Myers, Moderna, 2seventy bio, Amylyx Pharmaceuticals and Syros Pharmaceuticals are part of the Zacks top Analyst Blog.

    Zacks Investment Research
    Featured Companies: BMY MRNA
  • Biotech Stock Roundup: MRNA Up on Vaccine Data, BMY's Updates & More News

    Moderna (MRNA) and Bristol Myers (BMY) are in focus on pipeline and regulatory updates.

    Zacks Investment Research
    Featured Companies: BMY MRNA
Dividend data last updated 06/07/2025 04:46:48 UTC